Inclusion Criteria:

          -  Participants with a histologically confirmed diagnosis of:

        Phase 1b:

          -  Advanced solid tumors where nivolumab is indicated as per the latest nivolumab
             Prescribing Information,

        Phase 2:

          -  Metastatic NSCLC, progressing on or after prior pembrolizumab therapy with or without
             chemotherapy, irrespective of PD-L1 expression Patients with EGFR or ALK genomic tumor
             aberrations should have disease progression on FDA-approved therapy for these
             aberrations.

          -  Recurrent or metastatic HNSCC progressing on or after prior pembrolizumab therapy with
             or without chemotherapy

          -  HCC progressing after any prior therapy.

        Exclusion Criteria:

          -  Active, known or suspected autoimmune disease. Participants with vitiligo, type I
             diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring
             hormone replacement, psoriasis not requiring systemic treatment, or conditions not
             expected to recur in the absence of an external trigger are permitted to enroll.

          -  Major surgery, open biopsy or significant traumatic injury ≤ 28 days prior to first
             administration of study intervention. Central line surgery is not considered major
             surgery

          -  Symptomatic metastatic brain or meningeal carcinomatosis or tumors unless the
             participant is > 6 months from definitive therapy (surgery or radiotherapy), has no
             evidence of tumor growth on an imaging study and is clinically stable with respect to
             the tumor at the start of study intervention.

          -  Other malignancy within the last 5 years except for the following, which are
             permitted:

               -  curatively treated basal cell/squamous cell skin cancer,

               -  carcinoma in situ of the cervix,

               -  superficial transitional cell bladder carcinoma (if BCG [Bacillus
                  Calmette-Guerin] treatment was given, there should be a minimum of 6 months
                  between last dose and enrollment),

               -  in situ ductal carcinoma of the breast after complete resection,

               -  participants with localized, resected and/or low-risk prostate cancer may be
                  eligible after discussion with the sponsor's designated medical representative
                  and sponsor's approval.

          -  Other protocol inclusion/exclusion criteria may apply